Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score
暂无分享,去创建一个
A. Branzi | C. Rapezzi | T. Palmerini | S. Rosmini | M. B. Bacchi Reggiani | A. Marzocchi | F. Saia | C. Marrozzini | N. Taglieri | C. Moretti | Laura Alessi | P. Guastaroba | F. Vagnarelli | L. Cinti | M. Montefiori
[1] G. Stone,et al. Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions: Analysis From the Harmonizing Outcome With Revascularization and Stent in Acute Myocardial Infarction Trial , 2011, Circulation.
[2] R. Califf,et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[3] H. White,et al. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial , 2011, Journal of Thrombosis and Thrombolysis.
[4] Ewout W Steyerberg,et al. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.
[5] Michael J. Pencina,et al. Statistical methods for assessment of added usefulness of new biomarkers , 2010, Clinical chemistry and laboratory medicine.
[6] F. Van de Werf,et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). , 2010, European heart journal.
[7] A. Kastrati,et al. Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. , 2009, Clinical science.
[8] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[9] Luigi Ferrucci,et al. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. , 2007, Journal of the American College of Cardiology.
[10] K. Eagle,et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.
[11] J. Núñez,et al. Prognostic usefulness of white blood cell count on admission and one-year outcome in patients with non-ST-segment elevation acute chest pain. , 2006, The American journal of cardiology.
[12] Fred S Apple,et al. Biomarkers in acute cardiac disease: the present and the future. , 2006, Journal of the American College of Cardiology.
[13] B. Coller. Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality: Is It Time to Intervene? , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[14] K. Eagle,et al. Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). , 2004, American heart journal.
[15] Á. Avezum,et al. Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.
[16] Deepak L. Bhatt,et al. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. , 2003, The American journal of cardiology.
[17] F. Neumann,et al. White blood cell count and long term mortality after non-ST elevation acute coronary syndrome treated with very early revascularisation , 2003, Heart.
[18] U. Ikeda. Inflammation and coronary artery disease. , 2003, Current vascular pharmacology.
[19] M. Sabatine,et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes , 2002 .
[20] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[21] S. Diamond,et al. Neutrophil Enhancement of Fibrin Deposition Under Flow Through Platelet-Dependent and -Independent Mechanisms , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[22] R. D'Agostino,et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.
[23] E. Braunwald,et al. Association Between White Blood Cell Count, Epicardial Blood Flow, Myocardial Perfusion, and Clinical Outcomes in the Setting of Acute Myocardial Infarction: A Thrombolysis In Myocardial Infarction 10 Substudy , 2000, Circulation.
[24] J. Mehta,et al. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. , 1998, Journal of the American College of Cardiology.
[25] F. Harrell,et al. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .
[26] Alexander Rw. Inflammation and Coronary Artery Disease , 1994 .
[27] Baris Gencer,et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .
[28] L. Becker. Myocardial Reperfusion Injury , 2004, Journal of Thrombosis and Thrombolysis.
[29] S. Anker,et al. Immune and neurohormonal pathways in chronic heart failure. , 2002, Congestive heart failure.